



# UNITED STATES PATENT AND TRADEMARK OFFICE

JK

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/996,275	11/28/2001	Frank R. Sharp	10738-29	2341
24256	7590	10/12/2005	EXAMINER	
DINSMORE & SHOHL, LLP 1900 CHEMED CENTER 255 EAST FIFTH STREET CINCINNATI, OH 45202			FREDMAN, JEFFREY NORMAN	
			ART UNIT	PAPER NUMBER
			1637	
DATE MAILED: 10/12/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/996,275	SHARP ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Jeffrey Fredman	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 10 August 2005.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-93 is/are pending in the application.
- 4a) Of the above claim(s) 18,19,23-28,30-37 and 43-93 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-17,20-22,29 and 38-42 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All
  - b) Some \*
  - c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____  |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date. <u>512102</u> | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|  | 6) <input type="checkbox"/> Other: _____                                    |

**DETAILED ACTION**

***Election/Restrictions***

1. Applicant's election with traverse of the species elections in the reply filed on August 10, 2005 is acknowledged. The traversal is on the ground(s) that there is no burden in search the scope of the entire invention. This is not found persuasive because there is significant burden in searching the entire invention, since separate searches would be required for each of the individual species. Applicant's argument on enablement is also incorrect since the fact that a generic claim may be enabled does not enable all of the species of necessity. Generically, drugs are useful to treat medical conditions like stroke. That does not mean that every drug will be useful to treat stroke. Similarly, a diagnostic technique may work on many, but not all, species. Lastly, given that Applicant does not even provide the names of all of the dozens or hundreds of genes in the tables, making analysis of these tables extremely difficult, there is unquestionably a search burden in examining multiple different species.

With regard to the microarray type, there is a very significant burden between nucleic acid and protein microarrays since these differ in structure and in use and since the art relies upon these arrays for different purposes. This election is not a "species genus" type and claims to protein microarrays will not be examined in this application, even if nucleic acid microarrays were found allowable.

With regard to the final election, Applicant admits that the genes are not novel, therefore, this restriction is withdrawn.

In conclusion, claims 1-17, 20-22, 29 and 38-42 are elected and will be examined, including the generic claims. Claims 18, 19, 23-28, 30-37 and 43-93 are drawn to non-elected inventions and are withdrawn from further consideration.

The requirement is still deemed proper and is therefore made FINAL.

***Information Disclosure Statement***

2. The information disclosure statement filed March 12, 2005 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered.

The IDS is signed with regard to the patent documents, which were considered. The remaining documents were not provided and therefore are not considered.

***Claim Interpretation***

3. The term "injury database" is defined in the specification as "a database comprising a pattern of expression (see page 13, lines 16-17)." The term "database" is not defined by the specification, but a database is a "organized collection of information". So any collection of information will meet this "database" limitation.

***Claim Rejections - 35 USC § 112***

4. Claims 1-17, 20-22, 29 and 38-42 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The use of Genbank accession numbers in claims renders the claims vague and indefinite because, unlike SEQ ID Nos, Genbank Accession numbers are not stable and can be changed at any time. This variation is even evidenced by one of the species specifically noted by Applicant in Table 1, Genbank Accession No: AF073839, in which Genbank states "On Nov 16, 1999 this sequence version replaced gi:3288880. (see attached)" In this case, there was a change from 671 to 672 basepairs, so the sequence disclosed in the Genbank reference prior to filing is not the same as the sequence which is currently in Genbank under the accession number AF073839. As MPEP 2173 notes "The primary purpose of this requirement of definiteness of claim language is to ensure that the scope of the claims is clear so the public is informed of the boundaries of what constitutes infringement of the patent." Therefore as a preliminary matter, it is indefinite which sequence is intended in the claim, since both sequences are referred to by the Genbank Accession No. AF073839. Further, since the Genbank accession numbers used in the claims are capable of changing at any time, so is the claim scope. So the boundaries of the claim will change whenever Genbank makes a revision to a record. This is not in compliance with the requirement that the scope of the claim be definite. Consequently, these claims are vague and indefinite under 35 U.S.C. 112, second paragraph.

***Claim Rejections - 35 USC § 102***

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

6. Claims 1-6, 8, 9, 11-17, 20-22, 29 and 38-42 are rejected under 35 U.S.C. 102(b) as being anticipated by Kostulas et al (Stroke (1998) 29:462-466).

Kostulas teaches a method of claims 1 and 38 of injury assessment in an individual (see abstract) comprising the steps:

(a) determining a pattern of expression exhibited by blood cells obtained from the individual (see page 463, column 1, subheading “preparation of blood MNC” and figures 1-3 and table I, where Kostulas determines the pattern of expression of the number of cells which express IL-8, MCP-1, MIP-1alpha and MIP-1beta),

(b) comparing the pattern of expression exhibited by the obtained blood cells to an injury database to assess the injury (see table 1, where expression of IL-8 was compared).

With regard to claim 2, Kostulas teaches analysis of stroke patients (see abstract).

With regard to claims 3-4, 39, Kostulas teaches the pattern of gene expression of IL-8 (see table 1).

With regard to claim 5, Kostulas teaches analysis of peripheral blood samples (see page 463, column 1).

With regard to claim 6, 20-22, 29, and 40, Kostulas forms a pattern of expression, which is elevated IL-8 levels and unchanged MCP-1 levels (see table 1).

With regard to claims 8-9, Kostulas teaches ranking the expression levels of the expressed mRNAs (see table 1).

With regard to claim 11, Kostulas performs statistical analysis to determine the P value (see page 463, column 2 and table 1).

With regard to claims 12-13, 15, 42, Kostulas teaches the use of chemokines and demonstrates that IL-8 is hypoxia induced (see table 1, IL-8 and page 462, column 2).

With regard to claims 13-17, Applicant has admitted that "In fact, the genes providing the data points are already in the public domain and the Applicants do not assert their novelty or patentability. (see page 4 of response on August 10, 2005)."

With regard to claim 41, Kostas teaches Ischemic stroke (see title).

7. Claims 1-17, 20-22 adn 29 are rejected under 35 U.S.C. 102(e) as being anticipated by Das et al (U.S. Patent 6,316,197)

Das teaches a method of claims 1 and 38 of injury assessment in an individual (see abstract where the injury is exposure to a toxic agent) comprising the steps:

(a) determining a pattern of expression exhibited by blood cells obtained from the individual (see figure 33B and column 3, lines 42-67),

(b) comparing the pattern of expression exhibited by the obtained blood cells to an injury database to assess the injury (see column 3, lines 42-67).

With regard to claim 2, Das teaches analysis of anthrax infected blood (see figure 33B).

With regard to claims 3-4, Das teaches the pattern of gene expression of HCl and EIF-1 (see figure 33B and see column 12, line 56 to column 13, line 22, where Das teaches that dozens of genes in peripheral blood are responsive to SEB (which includes lipopolysaccharide) and to Anthrax).

With regard to claim 5, Das teaches analysis of peripheral blood samples (see column 12, line 56 to column 13, line 22).

With regard to claim 6, 20-22 and 29, Das forms a pattern of expression, (see column 3, lines 42-67 and column 12, lines 61-62 "We observed that the *in vivo* response reflected the pattern of altered gene expression that we had seen *in vitro*.").

With regard to claims 7, 10, Das teaches the steps of i) isolating RNA from the blood cells (see column 19, lines 40-41), ii) preparing a labelled probe using the isolated RNA (see column 21, lines 15-43), iii) applying the probe to a microarray (see column 21, lines 15-43) and iv) measuring the level of the RNA (see column 21, lines 15-43).

With regard to claims 8-9, Das teaches ranking the expression levels of the expressed mRNAs (see column 3, lines 42-67 and column 12, lines 61-62 "We observed that the in vivo response reflected the pattern of altered gene expression that we had seen in vitro.").

With regard to claim 11, Das teaches class prediction (see column 16, line 22, where genes acted as markers which "predicted" the pattern of illness).

With regard to claims 12-15, Das teaches the use of chemokines like interleukin 5 (a glycosylated protein) (see table 3) and interleukin 6 (see table 1).

With regard to claims 13-17, Applicant has admitted that "In fact, the genes providing the data points are already in the public domain and the Applicants do not assert their novelty or patentability. (see page 4 of response on August 10, 2005)."

***Claim Rejections - 35 USC § 103***

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation

Art Unit: 1637

under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

10. Claims 1-17, 20-22, 29 and 38-42 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kostulas et al (Stroke (1998) 29:462-466) in view of Lockhart et al (U.S. Patent 6,040,138) .

Kostulas teaches a method of claims 1 and 38 of injury assessment in an individual (see abstract) comprising the steps:

- (a) determining a pattern of expression exhibited by blood cells obtained from the individual (see page 463, column 1, subheading "preparation of blood MNC" and figures 1-3 and table I, where Kostulas determines the pattern of expression of the number of cells which express IL-8, MCP-1, MIP-1alpha and MIP-1beta),
- (b) comparing the pattern of expression exhibited by the obtained blood cells to an injury database to assess the injury (see table 1, where expression of IL-8 was compared).

With regard to claim 2, Kostulas teaches analysis of stroke patients (see abstract).

With regard to claims 3-4, 39, Kostulas teaches the pattern of gene expression of IL-8 (see table 1).

With regard to claim 5, Kostulas teaches analysis of peripheral blood samples (see page 463, column 1).

With regard to claim 6, 20-22, 29, and 40, Kostulas forms a pattern of expression, which is elevated IL-8 levels and unchanged MCP-1 levels (see table 1).

With regard to claims 8-9, Kostulas teaches ranking the expression levels of the expressed mRNAs (see table 1).

With regard to claim 11, Kostulas performs statistical analysis to determine the P value (see page 463, column 2 and table 1).

With regard to claims 12-13, 15, 42, Kostulas teaches the use of chemokines and demonstrates that IL-8 is hypoxia induced (see table 1, IL-8 and page 462, column 2).

With regard to claims 13-17, Applicant has admitted that "In fact, the genes providing the data points are already in the public domain and the Applicants do not assert their novelty or patentability. (see page 4 of response on August 10, 2005)."

While Kostulas teaches the injury assessment method as discussed above, Kostulas does not teach the elements of claims 7 and 10 and does not teach application of the method to microarrays, which is a clear intent of the invention, though the limitation never currently appears in the claims.

Lockhart teaches a method of analyzing expression of nucleic acids whose expression is altered in a disease state (see column 10, lines 30-32) comprising the steps:

(a) determining a pattern of expression using a microarray (see column 9, lines 25-35) exhibited by blood cells (see column 11, line 48),

(b) comparing the pattern of expression to a database to assess the injury (see column 25, lines 18-25, for example).

With regard to claim 7, Lockhart expressly teaches the steps of i) isolating RNA from the cells (see column 4, lines 8-10), ii) preparing a labelled probe using the isolated RNA (see column 3 and column 4, lines 8-11), iii) applying the probe to a microarray (see column 4, lines 1-7) and iv) measuring the level of the RNA (see column 4, lines 54-67) (this method is also taught in columns 11-17 and example 1).

With regard to claim 10, Lockhart expressly teaches labeling the cDNA product (see column 13, lines 50-65, for example).

With regard to claims 12-15, Lockhart teaches the use of chemokines like interleukin 6, a glycosylated protein (see table 1).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use a microarray and microarray methods of Lockhart to analyze the gene expression in stroke as discussed by Kostulas since Lockhart notes "It will be appreciated that the methods of this invention can be used to monitor (detect and/or quantify) the expression of any desired gene of known sequence or subsequence. Moreover, these methods permit monitoring expression of a large number of genes simultaneously and effect significant advantages in reduced labor, cost and time. The simultaneous monitoring of the expression levels of a multiplicity of genes permits effective comparison of relative expression levels and identification of biological conditions characterized by alterations of relative expression levels of various genes. Genes of particular interest for expression monitoring include genes involved in

Art Unit: 1637

the pathways associated with various pathological conditions (e.g., cancer) and whose expression is thus indicative of the pathological condition (see column 4, lines 54-67)."

The ordinary practitioner, motivated by Kostulas to detect gene expression in stroke, would have been strongly motivated to use the microarray method of Lockhart to determine which genes were involved in stroke in order to permit diagnosis as taught by Lockhart.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Jeffrey Fredman  
Primary Examiner  
Art Unit 1637  
*19115*